98 results about "Osteomyelitis" patented technology

The invention discloses a long acting slow-release drug carrier material for therapy and repair of bone disease and preparation method; wherein, the components of the drug carrier material are 4-8 weight account of strontium-doped calcium polyphosphate, 1-3 weight account of chitosan drug-loaded microspheres and 1-3 weight account of chitosan; the preparation method of the compound drug carrier material for therapy of osteomyelitis and other bone diseases is that (1) the chitosan-acetic acid solution is prepared, (2) the strontium-doped calcium polyphosphate powder is put into the chitosan-acetic acid solution and dispersed evenly, (3) the prepared chitosan drug-loaded microspheres is added, (4) the cross-linking agent is added for cross-linking, (5) freezing at temperature of 2-6 DEG C is processed for 12-48 hours, and (6) heating and drying are processed at temperature of 40-100 DEG C. The drug carrier material has the advantages of being applicable to therapy and repair of osteomyelitis and other bone diseases, releasing antibiotic for a long period, bone repair function, good biocompatibility and degradability, and ideal double function of therapy and repair of osteomyelitis and other bone diseases.

The invention relates to a metal bone graft material with a porous structure, and preparation and application thereof. The metal bone graft material is used as a filling material for transplantation after orthopaedic and oral damage and defects. The metal bone graft material contains the following trace elements in the human body by weight: 70.0 to 98.0 of Mg, 0.1 to 10.0% of Si, 0.1 to 10% of Sr and 0.1 to 10.0% of Ca, wherein the trace elements are uniformly distributed in a substrate and a coating. According to the invention, good ossification capability and matching in-vivo absorption capability are obtained by adjusting the contents of components in an alloy, controlling the shape, quantity and distribution of mesophase in metal, changing processing technology and surface coating protection of the alloy and preparing the porous structure; and the metal bone graft material has good biocompatibility and bone conduction capability, is a medical absorbent metal bone graft material with excellent mechanical properties, and is applicable to bone defects caused by wounds, malformation, bone tumors, osteomyelitis and joint displacement in clinical practice to promote bone restoration and applicable as a drug sustained release system.

The present invention relates to a slow-released preparation containing beta-lactamase inhibitor and cephalosporin. Said slow-released preparation can be made into antibiotic slow-released injection or slow-released implant preparation. Said injection is formed from slow-released microsphere and solvent, the slow-released microsphere contains slow-released auxiliary material and beta-lactamase inhibitor with antibacterial effective dose and cephalosporin, the solvent is special one containing suspension adjuvant of carboxymethyl cellulose sodium, etc. and its viscosity is 100 cp-3000 cp (20 deg.C-30 deg.C). The slow-released auxiliary material is selected from EVAc, polylactic acid copolymer, sebacic acid copolymer, albumin glue and gelatin, etc. The slow-released implant preparation is prepared by using slow-released microsphere or adopting melting process. Said invention also provides its application method. and can obtain obvious therapeutic effect for curing various infective diseases.

The present invention is directed to a monoclonal antibody that binds specifically to a Staphylococcus aureus glucosaminidase and inhibits in vivo growth of S. aureus. Also disclosed are monoclonal antibody binding portions, recombinant or hybridoma cell lines, pharmaceutical compositions containing the monoclonal antibody or binding portions thereof, and methods of treating 5*. aureus infection and osteomyelitis, and methods for introducing an orthopedic implant into a patient using the monoclonal antibody, binding portion, or pharmaceutical composition of the present invention.

The present invention provides an ointment for external application for curing various burns, scalds, wound ulcera, nonunion of wound and osteomyelitis with the obvious therapeutic effect, and its preparation process includes the following steps: placing 25 Chinese medicinal materials of lonicera flower, rhubarb, coptis root, phellodendron bark, gardenia fruit, Chinese ilex leaf, dried / fresh rehmannia and others as raw material in sesame oil with 360-400 deg.C, deep-frying until scorched, removing residue, adding beesmax to obtain paste-like material, cooling to 60 deg.C, addinkg cutch powder, borneol powder and musk powder, stirring them, high-temp. steam sterilizing and botting so as to obtain the invented ointment which is low in cost, can eliminate wound infection, can promote tissue regeneration, and can make healed wound have no obvious and clear scar.

The invention relates to a pain relieving fitness paste and a production method thereof which are mainly used for providing medication for treating the pain caused by osteomyelitis, arthritis and hyperosteogeny. The pain relieving fitness paste is prepared from 90-120g of radix salviae miltiorrhizae, 90-120g of safflower, 90-120g of caulis spatholobi, 90-120g of fructus gardeniae, 45-65g of radix clematidis, 45-65g of radix angelicae pubescentis, 45-65g of pricklyash peel, 130-165g of borneol, 90-120g of camphora and 90-120g of menthol crystal. The production method comprises the following steps of: grinding the radix salviae miltiorrhizae, safflower, caulis spatholobi, fructus gardeniae, radix clematidis, radix angelicae pubescentis and pricklyash peel into coarse powder; percolating the coarse powder with ethanol; concentrating the percolate into extract; extracting the dregs with gasoline to obtain extraction oil; preparing rubber paste, rosin, zinc oxide, wool fat, yellow vaseline, liquid paraffin, gasoline or SIS, liquid paraffin, glycerol ester of rosin and 2,6-butylated hydroxytoluene into a matrix; adding the extract, extraction oil, borneol, camphora and menthol crystal; and smearing the obtained product on the base cloth, covering with an anti-sticking layer, and slicing. Through the invention, the formula is scientific and reasonable, the active ingredients are maintained to the greatest degree, and the curative effect is improved.

The present invention relates to a slow-released preparation containing beta-lactamase inhibitor. Said slow-released preparation can be made into antibiotic slow-released injection or slow-released implant preparation. Said injection is formed from slow-released microsphere and solvent, said slow-released microsphere contains slow-released auxiliary material and beta-lactamase inhibitor with antibacterial effective dose and penicillin antibiotics, the solvent is special solvent containing suspension adjuvant of carboxymethyl cellulose sodium, etc. its viscosity is 100 cp-3000 cp (20 deg.C-30deg.C); the slow-released auxiliary material is selected from EVAc, polylactic acid copolymer, sebacic acid copolymer, albumin glue and glatin, etc. The slow-released implant preparation is prepared by using slow-released microsphere or adopting melting process. Said invention also provides its application range and can obtain obvious therapeutic effect for curing various infective diseases.

The slow released compound antituberculotic preparation contains at least one of rifampicin, pyrazinamide, kanamycin, isoniazide, rifapentine, etc. The slow released preparation is slow released injection or slow released implanting agent. The slow released injection consists of slow released microsphere and solvent, the slow released microsphere contains slow releasing supplementary material and antituberculotic, and the solvent is special solvent containing suspending agent carboxymethyl cellulose sodium and of viscosity of 100-3000 cp at 20-30 deg.c. The slow releasing supplementary material is EVAc, PLA, PLGA, sebacic acid copolymer, etc. The slow released compound antituberculotic preparation is set or injected into local tuberulosis focus to treat various kinds of intractable tuberulosis, and has medicine releasing period up to 30-40 days, less systemic toxicity and unique curative effect.

The present invention relates to a slow-released preparation containing macrolide antibiotics. Said slow-released preparation is slow-released injection or slow-released implant preparation. Said injection is composed of slow-released microsphere and solvent, said slow-released microsphere contains slow-released auxiliary material and macrolide antibiotics, the solvent is special solvent containing suspension adjuvant of carboxymethyl cellulose sodium, its viscosity is 100 cp-3000 cp (20 deg.C-30 deg.C); the slow-released auxiliary material is selected from EVAc, PLA, PLGA, sebacic acid copolymer, albumin glue and golatin, etc. The slow-released implant preparation is prepared by using slow-released microsphere or adopting melting process. Said invention also provides its application method, and can obtain obvious therapeutic effect for curing various infective diseases.

The present invention relates to a slow-released preparation of antibiotic for local application, it is slow-released injection or slow-released implant preparation. The injection is composed of slow-released microspheres and solvent, the slow-released microsphere contains slow-released auxiliary material and beta-lactamase inhibitor or tetracyclines, the solvent is a special solvent containing suspension adjuvant of sodium cellulose glycollate, etc. its viscosity is 100 cp -3000 cp (20-30 deg.C), the slow-released auxiliary material is selected from EVAc, PLA, PLGA, sebacic acid copolymer, albumin glue and gelatin. The slow-released implant preparation is prepared by using slow-released microspheres or adopting melting process. Said invention also provides its application range.

The invention relates to a lignin compound that could prevent yellow staphylococcal bacteria and B type hemolytic streptococcus, and the medicine combination of the compound. The invention of lignin Morgan dandehon herb acid A and Rufescidride has obviously effect restraining yellow staphylococcal and B type hemolytic streptococcus. It is also respected to prevent the diseases caused by them, like boil, blain, toxicity epidermis necrolysis, pneumonia, etc.

The invention relates to a slow-releasing agent of antibiotics containing aminoglycoside, comprising slow-releasing micro-sphere containing slow-releasing findings and aminoglycoside antibiotics, and special dissolvent containing suspending adjuvant agent such as sodium carboxymethyl cellulose with the adhesive degree being 100cp-3000cp (at 20-30 Deg. C). The slow-releasing findings comprises EVAc, polyphenyl, PLA, PLGA, decanedioic acid copolymer, albumen glue and gelatin; the slow-releasing micro-sphere can be produced to slow-releasing implanting agent and unguent agent. When the slow-releasing implanting agent and injection is placed or injected into bacteria, the medicine can be released slowly for more than 5-30 days, and toxicity is dramatically reduced at the same time when effective medicine concentration is got and maintained. The said slow-releasing agent is specially effective for chronic medullitis, bedsore, intractable ulcer on skin, diabetes femoral head necrosis and other abscessus, which are caused by Staphylococcus, Streptococcus, Streptococcus, acne Propionibacteriaceae, Enterobacter, Enterobacter, gonotoxin or parameningococcus.

The invention discloses a process for preparing polyanlydrides, carriers for hydrophilous antiphlogistic drug and antitumor agent by using binary aliphatic acid and dimer acid copolymerization, because the use of diacid with longer carbon chain as monomer, the degradation speed of the polyanlydride material is slow, and the medicinal release cycle is longer, thus is suitable for the local slow release administration treatment for osteomyelitis and solid tumor diseases.

The invention relates to methods and pharmaceutical compositions for the treatment of bone density related diseases. More particularly, the present invention relates to a ROBO1 modulator for use in a method for the treatment of a bone mineral density related disease in a subject. In a particular embodiment the ROBO1 modulator is selected from the group consisting of small organic molecules, antibodies, aptamers or polypeptides. In another particular embodiment said bone mineral density related disease is selected from the group consisting of ghosal hematodiaphyseal dysplasia syndrome (GHDD), osteoporosis, osteoporosis associated to pseudoglioma, osteoporosis and oculocutaneous hypopigmentation syndrome, osteoporosis due to endocrinological dysfunction, osteogenesis imperfecta osteopenia, Paget's disease, osteomyelitis, hypercalcemia, osteonecrosis, hyperparathyroidism, lytic bone metastases, periodontitis, bone loss due to immobilization and osteoporosis associated with a disease selected from the group consisting of cachexia, anorexia, alopecia, rheumatoid arthritis, psoriatic arthritis, psoriasis, and inflammatory bowel disease.

Disclosed is a topical applicated antibiotics slow release agent as a slow release injection or a slow release implantation agent, comprising slow release microspheres and menstruum. Said release microsphere comprises slow release assist materials and antibiotics, and said menstruum is a special menstruum comprising suspending agents of sodium carboxymethylcellulose, etc, with a viscosity of 100cp-3000cp(at 20-30 DEG C). Said slow release assist materials are selected from the group of EVAc, polifeprosan, PLA, PLGA, sebacic acid copolymer, albumen glue, gelatin, and etc. Said slow release implantation agent is prepared with slow release microspheres or by melt method, etc. The disclosed slow release agent can release drugs for 10 days by topical applicated or injected at a focus, decreasing whole body toxicity obviously while obtaining and sustaining effective topical drug concentration at the focus.

The invention discloses a method for fixing a metaphysic bone defect by adopting a thin-needle semi-ring external fixing frame and VSD (Vacuum Sealing Drainage) lavage. The method for fixing the metaphysic bone defect by adopting the thin-needle semi-ring external fixing frame and the VSD lavage is characterized by comprising the thin-needle semi-ring external fixing frame and the VSD lavage, wherein the thin-needle semi-ring external fixing frame is composed of a semi-bent bow, a universal joint, an adjuster, a connecting rod, a steel needle fixing clamp and a steel needle and the VSD lavage is composed of a negative-pressure airtight auxiliary material, a semi-permeable wound surface sealing film, a negative-pressure attracting device and a medical infusion apparatus. According to the method for fixing the metaphysic bone defect by adopting the thin-needle semi-ring external fixing frame and the VSD lavage provided by the invention, the infection and osteomyelitis can be effectively prevented and treated and the delayed union and disconnection of bone are avoided.

The present invention provides an organic-inorganic self-solidified composite bone graft formed by a hydration bridge formation of a multi-trace element organic compound and an inorganic compound. Themulti-trace element organic compound is prepared by using a solution method, inorganic salts with different metastable-state structures are prepared by a heat treatment, the two materials are mixed and ground to form micro-nano powder, the micro-nano powder is mixed with water-containing solidified liquid to form a bridge structure by diffusion and a hydrated crystalline water structure by self-solidification, and thus a stable bone repair material is formed. The prepared bone graft can be shaped at will and has high strength, can provide various essential elements for bone tissue repair, hasgood biological properties, has a degradation rate consistent with a bone formation cycle, and finally can be completely absorbed by tissues to substitutably form new bones and obtains any desired compressive strengths and degradation cycles according to needs to adjust raw material composition ratios, and can be used as the repair material for bone defects caused by trauma, deformity, bone tumors, osteomyelitis or joint replacement, etc. clinically.

The invention discloses a flavonoid glycoside and medical salt and application to prevent Micrococcus pyogenes and beta hemolytic streptococcus, which is characterized by the following: preventing pustule, toxic epidermal decay, acute myocarditis, cystitis, cervicitis and tumour of neutral nerve system; fitting for treating prostatitis, pneumococcus, medullitis and knuckle disease.

The invention relates to a release injection which contains cefradine, wherein it is formed by release micro ball and dissolvent; the release micro ball contains release findings and penicillin antibiotic; the dissolvent is the special one contains sodium carboxymethyl cellulose as suspension agent; the viscosity is 100cp-3000cp (20Deg. C-30Deg. C); the release agent is selected from EVAc, polyphenyl, PLA, PLGA, sebacic acid polymer, protein pastern, and dope; the release micro ball can be made into release implant agent; the release implant agent and release injection is laid on bacteria stove or injected, to release the medicine for 5-30 days, to keep the effective medicine density and reduce the whole toxicity. The invention can be used to cure the infection caused by staphylococcus, streptococcus, etc.

The invention relates to application of ozonized oil in small surgical incisions or other wound such as mucosal ulcer, diabetic feet, cervical erosion, anal fissure, anus fistula, soft tissue injury,fall damage wound surface, recurrent wound, abscess, acne, arthritis, joint degeneration, cystitis, furunculosis, neurological disorder osteomyelitis, gangrene, ulcus cruris, synovitis, gout, sinusitis, spondylitis, scapulohumeral periarthritis, lumbocrural pain, periostitis and stomatitis. Through the modes of oral administration, intraperitoneal injection, clyster, gavage, intravenous injection,subcutaneous injection, intramuscular injection, external application, drop and suppository, the diseases can be effectively prevented and treated.

The invention relates to a slow-releasing agent or rslow-releasing implanting agent containing antibiotics. The injection comprises slow-releasing micro-sphere and dissolvent. The slow-releasing micro-sphere contains slow-releasing findings and antibiotics, and dissolvent contains suspending adjuvant agent such as sodium carboxymethyl cellulose with the adhesive degree being 100cp-3000cp (at 20-30 Deg. C). The slow-releasing findings comprises EVAc, polyphenyl, PLA, PLGA, decanedioic acid copolymer, albumen glue and gelatin; the slow-releasing implanting agent is prepared with slow-releasing micro-sphere or through other methods. When said antibiotics is placed or injected into bacteria, the medicine can be released slowly for more than 10 days, and toxicity is dramatically reduced at the same time when effective medicine concentration is got and maintained. The said slow-releasing agent is specially effective for chronic medullitis, bedsore, intractable ulcer on skin, diabetes femoral head necrosis and other abscessus, which are caused by Staphylococcus, Streptococcus, Streptococcus, acne Propionibacteriaceae, Enterobacter, Enterobacter, gonotoxin or parameningococcus.

The invention relates to an anti-tuberculosis Chinese medicine, a special adjuvant medicine and a preparation method thereof. Pharmaceutically-effective raw materials of the anti-tuberculosis Chinese medicine comprise blister beetle, drgon's bone, oyster, chicken gizzard-membrane, pumice and egg white of 10 eggs (yolk removed). The adjuvant medicine is water soaking liquid or water decoction of one or more selected from milkvetch root, licorice root, ginseng, radix codonopsis, milkvetch root, red jujube and wine-processed twotoothed achyranthes root. The medicine has the effects of removing blood stagnation and eliminating pathogenic accumulation, and is mainly used to treat pulmonary tuberculosis, tuberculous pleurisy, pyogenic osteomyelitis, bone tuberculosis, tuberculosis of thoracic and lumbar vertebra, lymphoid tuberculosis, tuberculous peritonitis, silicosis complicated with tuberculosis, and acute lymphadenitis.

The invention relates to application of a cyanoacrylate compound on the treatment of human and animal infectious diseases caused by fungus, particularly human and animal diseases such as skin diseases, keratitis, keratohelcosis, endophthalmitis, osteomyelitis, arthritis, sinus infection, onychomycosis, mycetoma and surgery or burning process infection caused by fusarium.

The invention discloses a composite hydrogel for promoting osteomyelitis healing, and a preparation method of the composite hydrogel comprises the following steps: mixing a mixed solution A containingcarboxymethyl chitosan and hyaluronic acid with a mixed solution B containing antibiotics and bone morphogenetic protein sustained-release microspheres, adding a crosslinking agent, and crosslinkingto obtain the composite hydrogel. The composite hydrogel disclosed by the invention is of a uniform porous reticular structure, can effectively promote wound healing, and has good bionic performance,biocompatibility, mechanical property and degradability. Moreover, the composite hydrogel disclosed by the invention can continuously release antibacterial antibiotics for a long time and induce bonemorphogenetic protein formed by new bones, infection can be effectively controlled, bone regeneration can be effectively promoted under the condition that no extra operation is conducted, the operation frequency is reduced, the treatment period is shortened, the physical and economic burdens of a patient are relieved, and the composite hydrogel has a good application prospect in osteomyelitis treatment.

The invention relates to a Chinese medicinal composition for treating osteomyelitis. The composition is prepared by 20 traditional Chinese medicines in a certain ratio by weight, i.e. Radix Rehmanniae Preparata, Salvia Miltiorrhiza, Morinda officinalis, honeysuckle, caulis spatholobi, Rhizoma et Radix Notopterygii, gypsum, radix cyathulae, rhizoma drynariae, ophiopogon root, dandelion, periostracan cicadae, Gynostemma pentaphyllum, Kudzuvine Root, motherwort, polygonatum, Folium Artemisiae argyi, Philippine Violet Herb, stiff silkworms, and rhizoma smilacis glabrae. And the Chinese medicinal composition provided in the invention has the characteristics of good and fast curative effects, convenient preparation and oral administration, high cure rate and the like.

The invention relates to a traditional Chinese medicine composition for treating bone tuberculosis and osteomyelitis. The traditional Chinese medicine composition comprises the following traditional Chinese medicine raw materials in parts by weight: 28-32 parts of earthworm, 28-32 parts of Astragalus root, 14-16 parts of Codonopsis pilosula, 14-16 parts of Angelica sinensis, 14-16 parts of pangolin, 8-12 parts of white paeony root, 14-16 parts of bighead atractylodes rhizome, 8-12 parts of spina gleditsiae, 8-12 parts of liquorice, 14-16 parts of prepared rhizome of rehmannia, 28-32 parts of rhizoma alismatis and 8-12 parts of Poria cocos. The traditional Chinese medicine composition disclosed by the invention is an oral medicine preparation form of each conventional traditional Chinese medicine containing a medicinal auxiliary material or not, preferably a powder preparation or a capsule preparation. The traditional Chinese medicine composition disclosed by the invention has obvious curative effects on the tuberculosis and the osteomyelitis, which are caused by various reasons; and compared with the existing traditional Chinese medicine prescription, the traditional Chinese medicine composition has the advantages of quick effect, short course of treatment and no toxic side effects.

The slow released compound antituberculotic preparation containing synergist is implanting agent or slow released injection comprising slow released microsphere and solvent. The slow released microsphere consists of slow releasing supplementary material, at least one antituberculotic selected from rifampicin, isoniazid and pyrazinamide and at least one antituberculotic synergist selected from cycloserine, ofloxacin, ciprofloxacin, sparfloxacin and capreomycin. The solvent is special solvent containing suspending agent carboxymethyl cellulose, etc. and with viscosity of 100-3000 cp at 20-30 deg.c. The slow releasing supplementary material is selected from EVAc, PLA, PLGA, etc. The slow released compound antituberculotic preparation can release antituberculotic in the local tubercolosis part for 30-40 days so as to maintain the local effective medicine concentration while lowering systemic toxicity. The present invention has obvious unique treating effect on various kinds of intractable tuberulosis.

The invention discloses a traditional Chinese medicine for treating acute purulent osteomyelitis and a preparation method of the traditional Chinese medicine. The traditional Chinese medicine comprises the following traditional Chinese medicine raw materials: kudzuvine root, dark plum, radices trichosanthis, membranous milkvetch root, gypsum rubrum, rhizoma anemarrhenae, dayflower, cape jasmine fruit, baical skullcap root, garden burnet, Stachys kouyangensis, giant knotweed, Chinese fever vine, Begonia bretschneideriana Hemsl, Pittosporum sahnianum Gowda, coptis, gentian, Thalictrum petaloideum, RhizomaParidis, Sargentodoxa cuneata, radix tinosporae, potentilla discolor, figwort, Callicarpa bodinieri Levl, Carpesium abrotanoides, panax notoginseng, Agrimonia pilosa Ledeb, turmeric and Liquidambar formosana Hance. The invention has the benefits that the traditional Chinese medicine has the effects of clearing heat-toxin, replenishing and cooling blood, and relieving pain, has a short course of treatment without recurrence after cure, can improve immunity of the human body, is convenient in manufacturing technology, low in toxic or side effects, is easy to manufacture, and is low in cost.

The invention discloses a traditional Chinese medicine for treating osteomyelitis and a preparation method of the traditional Chinese medicine. The traditional Chinese medicine comprises the following components in parts by weight: 1-3 parts of calculus bovis, 5-7 parts of centipede, 8-10 parts of typhonium giganteum, 4-6 parts of akebia trifoliata koidz, 10-12 parts of impatiens balsamina, 7-9 parts of peony, 10-15 parts of poria, 10-12 parts of myrrh, 5-7 parts of sangusis draconis, 9-11 parts of viola inconspicua, 1-3 parts of semen cuscutae, 3-5 parts of panax notoginseng, 8-10 parts of styphnolobium japonicum, 10-12 parts of mulberry branch, 2-5 parts of herba epimedii, 6-8 parts of ligusticum wallichii, 1-3 parts of manis pentadactyla, 9-11 parts of rhizoma acori graminei, 10-20 parts of peppermint leaf, 5-7 parts of phryma leptostachya, 3-5 parts of panax quinquefolium, 7-9 parts of radix achyranthis bidentatae and 8-10 parts of hypericum japonicum. Partial hydropathic compress is carried out to the wound surface of osteomyelitis by the traditional Chinese medicine for detoxifying and tonifying qi, removing slough and promoting growth of tissue regeneration and tonifying vital energy, so that the immunity of a human body is improved, and disease resistance of the human body to external evil and poison is enhanced. The traditional Chinese medicine has advantages of good treatment effect, short course of treatment and small pain of patients.